First Case of Clade I Mpox Confirmed in Canada

On November 22, 2024, the Public Health Agency of Canada (PHAC) confirmed the first case of clade I mpox in Canada. The case was identified in an individual in Manitoba who had recently traveled from a region experiencing an outbreak in central and eastern Africa. The individual is currently isolating and a public health investigation, including contact tracing, is underway.

The National Microbiology Laboratory confirmed the presence of mpox clade Ib in the sample from the individual. This marks the first case of clade I mpox in Canada, although clade II mpox has been present in the country since 2022.

PHAC has stated that the risk to the general population remains low. The agency is collaborating with Manitoba's public health authorities to monitor the situation and will provide updates as necessary.

Mpox is a viral infection that can cause a painful rash and other symptoms such as fever and muscle pain. It is contagious, and those in close contact with infected individuals, particularly if they have visible lesions, are at higher risk. Vulnerable groups include children, pregnant individuals, and those with compromised immune systems.

Currently, vaccination is not recommended for the general public, but it is advised for those at high risk of exposure. The Government of Canada has assured that there is an adequate supply of mpox vaccines to support prevention efforts across provinces and territories.

Preventive measures include avoiding close contact with infected individuals and their personal items. Travelers to affected regions are advised to follow health guidelines to minimize risk.